Improved AAV9-based gene therapy design for <i>SURF1</i>-related Leigh syndrome with minimal toxicity.

Mol Ther Methods Clin Dev · 2025 · PMC12398787 · PMID 40893166

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In heart tissue, AAV9/JeTI-h SURF1 v2 showed a trend of higher COX activity than AAV9/CBh-h SURF1 v1-treated mice.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Improved AAV9-based gene therapy design for &lt;i&gt;SURF1&lt;/i&gt;-related Leigh syndrome with minimal toxicity.

The sentences

Improved AAV9-based gene therapy design for <i>SURF1</i>-related Leigh syndrome with minimal toxicity.